Smital Shah - 09 Mar 2026 Form 4 Insider Report for Lyell Immunopharma, Inc. (LYEL)

Role: Chief Fin. and Bus. Officer
Signature: /s/ Mark Meltz, Attorney-in-Fact
Issuer symbol: LYEL
Transactions as of: 09 Mar 2026
Net transactions value: $0
Form type: 4
Filing time: 16 Mar 2026, 19:26:24 UTC
Previous filing: 17 Jun 2024
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Shah Smital	Chief Fin. and Bus. Officer	C/O LYELL IMMUNOPHARMA, INC., 201 HASKINS WAY, SUITE 101, SOUTH SAN FRANCISCO	/s/ Mark Meltz, Attorney-in-Fact	16 Mar 2026	0001808821

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	LYEL	Option (right to buy)	Award		+140,000		$0.000000^*	140,000	09 Mar 2026	Common Stock	140,000	$25.50	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	25% of the option shares will vest on March 9, 2027, with the remaining option shares to vest in equal monthly installments over the following 36 months, subject to the reporting person providing service through the applicable vesting date.